For clinicians
GHRP-6 for prescribers: status, evidence and what FDA has said
A neutral reference. It reports GHRP-6's regulatory status, the quality of its human evidence and what FDA has said about it. It does not suggest a dose, a protocol or a source.
Status reviewed 2026-10-01 · By the Grey Peptides Editorial Board · Regulatory fields generated from our tracker
| Also known as | — |
| FDA approval | Not FDA-approved |
| Compounding (503A) | Category 3 (nominated without adequate support): not compoundable; 503B Category 2 |
| Outsourcing (503B) | 503B Category 2: FDA has identified significant safety risks |
| WADA 2026 List | Prohibited (S2.2.4) |
| WADA 2027 List | Prohibited (S2.2.4) |
| Evidence grade | Medium |
| Status reviewed | 2026-10-01 |
What FDA has said
FDA lists Growth hormone releasing peptide-6 (GHRP-6) in Category 2, the substances it has found may present significant safety risks (page current as of 2026-04-22). In FDA's words:
Compounded drugs containing GHRP-6 may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has identified limited safety-related information, but the available data reveal safety concerns including potential effect on cortisol and increase in blood glucose due to decreases in insulin sensitivity.
Monitoring: what the literature does and does not say
- No label. GHRP-6 has no FDA-approved label, and therefore no labelled guidance on monitoring.
- What FDA has said about its risks is quoted above, from its list of bulk substances that may present significant safety risks.
These are gaps, not a monitoring schedule. This page does not supply one, and for a compound in this position the human evidence would not support one.
Compounding: where it stands
Today's position for GHRP-6: Category 3 (nominated without adequate support): not compoundable; 503B Category 2. An FDA advisory committee's vote is a non-binding recommendation; until FDA acts, a vote does not change what may be compounded. Our explainer on the 503A and 503B categories sets out what each status means, and the regulatory tracker is updated as FDA acts.
The evidence
The original growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), described by Bowers in 1984 and later the template for non-peptide secretagogues such as MK-0677.
The encyclopedia entry lists the human and animal studies we hold, each with its PMID.
What this page leaves out
Doses, regimens, cycle lengths and sources. That is deliberate. A reference that reports status and evidence is useful only if it is not also a protocol, and for a compound in this position there is no approved one to report.
Sources
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 2026-04-22; read 2026-10-01. FDA
- Grey Peptides regulatory tracker, row for GHRP-6, reviewed 2026-10-01. Tracker · dataset
- World Anti-Doping Agency. Prohibited List 2027, dated August 26, 2026, in force January 1, 2027. WADA
This page is a reference for qualified professionals. It is not medical advice, it does not recommend any treatment, and it is not a substitute for the prescriber's own judgement and their state and federal obligations.
Others in this group: AOD-9604 · Cathelicidin (LL-37) · Cerebrolysin · CJC-1295 · Dihexa · GHK-Cu (injectable) · Hexarelin · Ipamorelin · Melanotan II · MK-677 (ibutamoren) · Noopept · PEG-MGF · Pralmorelin (GHRP-2) · Selank · Sermorelin · Tesofensine · Thymopentin · Thymosin α-1